- Home
- JANX vs PCH Comparison
JANX vs PCH Comparison
Compare JANX & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | PCH |
|---|---|---|
| Founded | 2017 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 3.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | JANX | PCH |
|---|---|---|
| Price | $13.80 | $40.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 6 |
| Target Price | ★ $60.27 | $45.67 |
| AVG Volume (30 Days) | ★ 3.4M | 537.1K |
| Earning Date | 11-06-2025 | 01-26-2026 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | N/A | ★ 312.61 |
| EPS | N/A | ★ 0.82 |
| Revenue | $10,000,000.00 | ★ $1,115,571,000.00 |
| Revenue This Year | N/A | $3.66 |
| Revenue Next Year | N/A | $1.27 |
| P/E Ratio | ★ N/A | $48.68 |
| Revenue Growth | N/A | ★ 5.40 |
| 52 Week Low | $13.76 | $36.82 |
| 52 Week High | $61.59 | $48.12 |
Technical Indicators
Market Signals| Indicator | JANX | PCH |
|---|---|---|
| Relative Strength Index (RSI) | 27.41 | 51.39 |
| Support Level | $13.82 | $39.02 |
| Resistance Level | $14.49 | $40.35 |
| Average True Range (ATR) | 0.51 | 0.93 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 3.20 | 39.24 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.